Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Asthma, Copd
Inhaler Trainer Efficacy Study
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training.
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Trial name
- NCT06461403
- Testing
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Koronis Biomedical Technologies
Chronic Obstructive Pulmonary Disease
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50 µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours 15 min and 23 hours 45 min post QVA149…
- Trial name
- NCT01709903
- Testing
- QVA149, Fluticasone/salmeterol
- Where
- 55 sites in Argentina, Chile and 2 more
- Volunteers
- 744 people
- Sponsor
- Novartis Pharmaceuticals
COPD
In This Study, the Sponsor Would Like to Collaborate with Institution and Investigator to Aggregate Participants Data and to Pilot Its Software Algorithm Using Machine Learning and Threshold Based Methods for Predicting Exacerbations and Deterioration Within a 60 Days Period Post-discharge
In this study, the sponsor would like to collaborate with Institution and Investigator to aggregate participants data and to pilot its software algorithm using machine learning and threshold based methods for predicting…
- Trial name
- NCT06798688
- Testing
- A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations
- Volunteers
- 20 people
- Sponsor
- Respiree Pte Ltd
COPD
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe…
- Trial name
- GOLDEN7 (NCT02512302)
- Testing
- SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler®
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the…
- Trial name
- AERIFY-1 (NCT04701983)
- Testing
- Itepekimab SAR440340
- Where
- 232 sites in United States, Argentina and 19 more
- Volunteers
- 1,127 people
- Sponsor
- Sanofi
Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
The primary objective of this observational study is to determine the incidence of medically attended (inpatient or outpatient) acute respiratory illnesses or events leading to worsening cardiorespiratory status (ie, acute…
- Trial name
- CD-1089 (NCT01455402)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 476 people
- Sponsor
- MedImmune LLC
Asthma, COPD
Observational Study of Obstructive Lung Disease (NOVELTY)
The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis…
- Conditions
- Asthma, COPD, Chronic Obstructive Pulmonary Disease
- Trial name
- NOVELTY (NCT02760329)
- Testing
- Blood draw, Urine, Lung function measurements
- Where
- 331 sites in United States, Argentina and 17 more
- Volunteers
- 12,255 people
- Sponsor
- AstraZeneca
COPD
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.
- Trial name
- NCT00691405
- Testing
- Arformoterol tartrate inhalation solution
- Where
- 31 sites in United States
- Volunteers
- 215 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic…
- Trial name
- NCT03414541
- Testing
- DS102
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Afimmune
COPD
Bioequivalence Study of Tiotropium Bromide Inhalation Powder
This study is to characterize the pharmacodynamic characteristics and to assess the therapeutic bioequivalence after single dose of Tiotropium Bromide Inhalation Powder-test relative to Tiotropium Bromide Inhalation…
- Trial name
- NCT05161156
- Testing
- Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product)
- Where
- 17 sites in United States, India and 1 more
- Volunteers
- 306 people
- Sponsor
- Phargentis SA
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
To determine if ABX-IL8 will improve shortness of breath.
- Trial name
- NCT00035828
- Testing
- ABX-IL8
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Abgenix
Pulmonary Disease, Chronic Obstructive
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
The purpose of this study is to monitor the change in the health status of severe COPD patients after the initiation of Tiotropium therapy.
- Trial name
- NCT00624377
- Testing
- Tiotropium
- Where
- 17 sites in Taiwan
- Volunteers
- 2,031 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
- Trial name
- NCT01039675
- Testing
- 500mcg/25mcg once daily
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Respiratory Insufficiency
High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)
The aim of this study is to see if the Vapotherm High Flow Therapy (HFT) device is effective to provide breathing support to patients with Chronic Obstructive Pulmonary Disease or COPD.
- Trial name
- NCT00990119
- Testing
- Vapotherm High Flow Therapy, Non-invasive positive pressure ventilation
- Where
- United States
- Sponsor
- Vapotherm, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of UMEC (62.5 microgram[mcg]) when administered once-daily via dry powder inhaler (DPI) to Inhaled…
- Trial name
- NCT02257372
- Testing
- UMEC DPI, ICS/LABA medication, Albuterol/salbutamol Metered Dose Inhaler (MDI)
- Where
- 28 sites in Czechia, Germany and 2 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Indacaterol 150 µg Versus Formoterol
The study will be a 12 week treatment (84 days), parallel group, randomized, double blind, double dummy, study to assess the superiority of indacaterol (150 μg o.d.) versus formoterol (12 μg b.i.d.) in terms of trough forced…
- Trial name
- NCT01377428
- Testing
- Indacaterol, Formoterol
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study was to determine whether a fixed dose combination of indacaterol and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT02233543
- Testing
- QVA149
- Where
- 5 sites in Denmark, Norway and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.
- Trial name
- NCT01227278
- Testing
- Benralizumab 100 mg
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- MedImmune LLC
Bronchiectasis Adult, COPD
Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.
- Trial name
- NCT06937216
- Testing
- Volara therapy
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Baxter Healthcare Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.